ArticleMolecular biology reports2010
Impact of BTG2 expression on proliferation and invasion of gastric cancer cells in vitro.
Article in Molecular biology reports, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 66 citations in OpenAlex.
- PC3/Tis21/BTG2 and BTG1 genes: regulators of the cell cycle and neurogenesis, as well as tumor suppressors in malignant brain tumors.Frontiers in cell and developmental biology · 2026Review
- Identification of key hub genes associated with anti-gastric cancer effects of lotus plumule based on machine learning algorithms.World journal of gastrointestinal oncology · 2025Article
- Mir-25 Promotes Metastasis of Esophageal Cancer by Targeting BTG2.Applied biochemistry and biotechnology · 2023Article
- A novel circRNA, hsa_circ_0069382, regulates gastric cancer progression.Cancer cell international · 2023Article
- BTG2 as a tumor target for the treatment of luminal A breast cancer.Experimental and therapeutic medicine · 2022Article
- Expression and methylation status ofGastroenterology and hepatology from bed to bench · 2022Article
- B-Cell Translocation Gene 2 Upregulation Is Associated with Favorable Prognosis in Lung Adenocarcinoma and Prolonged Patient Survival.Journal of oncology · 2022Article
- Urinary Exosomal miRNAs as biomarkers of bladder Cancer and experimental verification of mechanism of miR-93-5p in bladder Cancer.BMC cancer · 2021Article
- MicroRNA-934 facilitates cell proliferation, migration, invasion and angiogenesis in colorectal cancer by targeting B-cell translocation gene 2.Bioengineered · 2021Article
- Unraveling the role of microRNA/isomiR network in multiple primary melanoma pathogenesis.Cell death & disease · 2021Article
- Expression and clinical significance of B cell translocation gene 2 in esophageal squamous cell carcinoma.International journal of clinical and experimental pathology · 2021Article
- DNA methylation profiling analysis identifies a DNA methylation signature for predicting prognosis and recurrence of lung adenocarcinoma.Oncology letters · 2019Article
- PKNOX2 suppresses gastric cancer through the transcriptional activation of IGFBP5 and p53.Oncogene · 2019Article
- Estradiol Prevents High Glucose-Induced β-cell Apoptosis by Decreased BTG2 Expression.Scientific reports · 2018Article
- Inhibition of TNFα-interacting protein α (Tipα)-associated gastric carcinogenesis by BTG2Experimental & molecular medicine · 2018Article
- MiR-25-3p promotes the proliferation of triple negative breast cancer by targeting BTG2.Molecular cancer · 2018Article
- A new long noncoding RNA (lncRNA) is induced in cutaneous squamous cell carcinoma and down-regulates several anticancer and cell differentiation genes in mouse.The Journal of biological chemistry · 2017Article
- Article
- MicroRNA‑21 regulates the expression of BTG2 in HepG2 liver cancer cells.Molecular medicine reports · 2015Article
- Isolation and characterization of circulating tumor cells from human gastric cancer patients.Journal of cancer research and clinical oncology · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BTG2 (B cell translocation gene 2) is downregulated in several human tumors and has been known as a tumor suppressor in carcinogenesis of thymus, prostate, kidney, and liver. However, little is known about the role BTG2 plays in gastric adenocarcinoma. In the present study, we intended to investigate the influence of BTG2 on the growth, proliferation, apoptosis, invasion and cell cycle of the gastric cancer cell lines SGC7901 and MKN45. BTG2 cDNA was insected into a constitutive vector pcDNA3.1 followed by transfection in gastric cancer cell line MKN45 and SGC7901 by using liposome. Then stable transfectants were selected and appraised. The apoptosis and cell cycles of these transfectants were analyzed by using flow cytometric assay. The growth and proliferation were analyzed by cell growth curves and colony-forming assay, respectively. The invasion of these clones was analyzed by using cell migration assay. MKN-BTG2 (MKN45 with stable transfection of BTG2 gene) and SGC-BTG2 (SGC7901 with stable transfection of BTG2 gene) grew slower than their control groups, respectively. The cell counts of MKN-BTG2 in the fourth, fifth, sixth and seventh days were significantly fewer than those of control groups (P < 0.05). Those of SGC-BTG2 in the fourth fifth, sixth and seventh days were significantly fewer than those of control groups too (P < 0.05). Cell cycle analysis showed that proportions of MKN-BTG2 and SGC-BTG2 cells in G0-G1 and S were different significantly with those of their control groups, respectively (P < 0.05). The apoptosis rate of MKN-BTG2 was significantly higher than those of control groups (P < 0.05). Results of colony-forming assay showed that the colon formation rates of MKN-BTG2 and SGC-BTG2 were lower than those of their control groups (P < 0.05). The results of cell migration assay showed that the cell migration rates of MKN-BTG2 and SGC-BTG2 were not significantly different with those of their control groups (P > 0.05). BTG2 can restrain the growth and proliferation of gastric cancer cells powerfully. It can reduce some malignant phenotype of these tumor cells. But it could not impact the ability of invasion of gastric cancer cells, so could not restrain the metastasis of gastric cancer. In gastric cancer, BTG2 could be thought as a tumor-inhibiting gene in some distance, so the gene could be a potential target of gene therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.